{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:00:19Z","timestamp":1747195219916,"version":"3.40.5"},"reference-count":19,"publisher":"XMLink","issue":"3","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C2750"],"award-info":[{"award-number":["HI14C2750"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1I1A1A01064906"],"award-info":[{"award-number":["NRF-2020R1I1A1A01064906"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["tcpharm.org"],"crossmark-restriction":false},"short-container-title":["Transl Clin Pharmacol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.12793\/tcp.2022.30.e13","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T06:58:19Z","timestamp":1664521099000},"page":"136","update-policy":"https:\/\/doi.org\/10.12793\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A randomized, open-label, single-dose, two-way crossover study to assess the pharmacokinetics between two tablets of fixed-dose combination formulation with raloxifene and cholecalciferol and concomitant administration of each agents in healthy male volunteers"],"prefix":"10.12793","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-5332","authenticated-orcid":false,"given":"Hae Won","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu 41944, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-3451","authenticated-orcid":false,"given":"Woo Youl","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu 41944, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5703-1615","authenticated-orcid":false,"given":"Mi-Ri","family":"Gwon","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu 41944, Korea."},{"name":"Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Jung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu 41944, Korea."},{"name":"Clinical Omics Institute, School of Medicine, Kyungpook National University, Daegu 41944, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Hee","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Nursing, Daegu Catholic University, Gyeongsan 38430, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyunghee","family":"Cho","sequence":"additional","affiliation":[{"name":"Analytical Research Division, Biocore Co. Ltd., Seoul 08511, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bakhwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Alvogen Korea Co. Ltd., Seoul 07326, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8872-3796","authenticated-orcid":false,"given":"Sook Jin","family":"Seong","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu 41944, Korea."},{"name":"Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-7579","authenticated-orcid":false,"given":"Young-Ran","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu 41944, Korea."},{"name":"Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18617","reference":[{"key":"10.12793\/tcp.2022.30.e13_ref1","first-page":"92","volume":"43","author":"Tu","year":"2018","journal-title":"P&T"},{"key":"10.12793\/tcp.2022.30.e13_ref2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"unstructured":"U.S. Food and Drug Administration. Evista\u00ae (raloxifene hydrochloride) prescribing information [Internet]. Accessed May 2, 2022.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022042lbl.pdf","key":"10.12793\/tcp.2022.30.e13_ref3"},{"key":"10.12793\/tcp.2022.30.e13_ref4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1043-2760(99)00176-9","volume":"10","author":"Avioli","year":"1999","journal-title":"Trends Endocrinol Metab"},{"key":"10.12793\/tcp.2022.30.e13_ref5","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.2147\/IJN.S259993","volume":"15","author":"Ye","year":"2020","journal-title":"Int J Nanomedicine"},{"key":"10.12793\/tcp.2022.30.e13_ref6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"10.12793\/tcp.2022.30.e13_ref7","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00198-016-3573-z","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.12793\/tcp.2022.30.e13_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.vh.2015.11.001","volume":"100","author":"DeLuca","year":"2016","journal-title":"Vitam Horm"},{"unstructured":"U.S. Food and Drug Administration. Hectorol\u00ae (doxercalciferol capsules) prescribing information [Internet]. Accessed May 24, 2022.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/020862s019,021027s013lbl.pdf","key":"10.12793\/tcp.2022.30.e13_ref9"},{"key":"10.12793\/tcp.2022.30.e13_ref10","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0091270010382010","volume":"51","author":"Denker","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.12793\/tcp.2022.30.e13_ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/derm.25531","volume":"5","author":"Karczmarewicz","year":"2013","journal-title":"Dermatoendocrinol"},{"key":"10.12793\/tcp.2022.30.e13_ref12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2474-8-3","volume":"8","author":"Deane","year":"2007","journal-title":"BMC Musculoskelet Disord"},{"key":"10.12793\/tcp.2022.30.e13_ref13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamapsychiatry.2016.1383","volume":"73","author":"Kulkarni","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.12793\/tcp.2022.30.e13_ref14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","volume":"14","author":"Morii","year":"2003","journal-title":"Osteoporos Int"},{"unstructured":"U.S. Food and Drug Administration. FOSAMAX\u00ae PLUS D (alendronate sodium\/cholecalciferol) prescribing information [Internet]. Accessed June 7, 2022.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021762s018lbl.pdf","key":"10.12793\/tcp.2022.30.e13_ref15"},{"key":"10.12793\/tcp.2022.30.e13_ref16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/cpdd.1062","volume":"11","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"unstructured":"US Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs \u2013 General Considerations [Internet]. Accessed June 7, 2022.  https:\/\/www.fda.gov\/media\/88254\/download","key":"10.12793\/tcp.2022.30.e13_ref17"},{"unstructured":"Guideline on. Bioequivalence Studies for Orally Administered Drug Products. (No. 2020-91): Korea Ministry of Food and Drug Safety (MFDS) [in Korean] [Internet]. Accessed June 7, 2022.  http:\/\/www.jbcp.kr\/bbs\/board.php?bo_table=reference&wr_id=5","key":"10.12793\/tcp.2022.30.e13_ref18"},{"key":"10.12793\/tcp.2022.30.e13_ref19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1208\/s12248-012-9378-x","volume":"14","author":"Mitra","year":"2012","journal-title":"AAPS J"}],"container-title":["Translational and Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tcpharm.org\/pdf\/10.12793\/tcp.2022.30.e13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2022.30.e13","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2022.30.e13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T07:06:32Z","timestamp":1664521592000},"score":1,"resource":{"primary":{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2022.30.e13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.12793\/tcp.2022.30.e13","relation":{},"ISSN":["2289-0882","2383-5427"],"issn-type":[{"type":"print","value":"2289-0882"},{"type":"electronic","value":"2383-5427"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"2022-06-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-31","name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-15","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"Copyright \u00a9 2022 Translational and Clinical Pharmacology","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"It is identical to the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/).","name":"license","label":"License","explanation":{"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}